miR-212 mimics

miR-212 mimics are synthetic RNA molecules engineered to replicate the function of endogenous microRNA-212 (miR-212), a member of the miR-212/132 cluster. Designed for research and potential therapeutic use, these mimics are typically introduced into cells to elevate miR-212 activity, thereby modulating the expression of miR-212 target genes. Mechanistically, miR-212 regulates gene expression via binding to complementary sequences, primarily in the 3' untranslated regions (3' UTR) of target mRNAs, resulting in translational repression or mRNA degradation. In cancer models, miR-212 mimics have shown context-specific effects: in non-small cell lung cancer (NSCLC), miR-212 mimics can promote cell proliferation and invasion by targeting genes such as PTCH1[2], while in prostate cancer, they suppress tumor growth and invasion by downregulating targets such as mitogen-activated protein kinase 1 (MAPK1)[4]. In the nervous system and psychiatric disease models, miR-212 mimics have been used to study and modulate synaptic plasticity and addiction-related behaviors[3], as well as to reduce neuronal apoptosis and depression-like behaviors by targeting nuclear factor I-A (NFIA)[5]. Delivery is mostly preclinical and experimental, often via transient transfection or viral vectors in vitro and in animal studies. No clinical trials or commercial drug products containing miR-212 mimics were identified as of August 2025.

Other names

miR-212mmiR212mmiR 212msynthetic miR-212 mimicmiR-212-3p mimicsmiR212-3p mimicsmiR 212-3p mimics